TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial

Core Insights - TransMedics Group, Inc. has received full FDA approval for its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial, following previous approvals for the OCS DENOVO Lung trial [1][3] - The ENHANCE trial aims to support prolonged heart perfusion and demonstrate the superiority of OCS Heart perfusion over traditional static cold storage methods, with a total sample size expected to exceed 650 patients, making it the largest heart preservation trial globally [2][3] Company Overview - TransMedics is a leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, focusing on improving organ quality and increasing the utilization of donor organs for patients with end-stage heart, lung, and liver failure [4]